Table 3 Impact of genetic and clinical variables on the overall survival and blast transformation free survival of 176 patients with PHF6 mutated (PHF6^MUT) myeloid neoplasms.

 Hemoglobin < 10 g/dl

5.6 (1.8–16.8)

<0.01

9.8 (2.4–39.9)

<0.01

 Complex/monosomal karyotype or chromosome 7 abnormalities

5.9 (1.3–27.5)

0.02

14.9 (2.3–94.8)

<0.01

 DNMT3A^MUT

5.1 (1.1–24.8)

0.04

13.8 (2.1–91.8)

<0.01

 NRAS^MUT

0.09 (0.01–0.7)

0.02

0.12 (0.01–1.1)

0.05

 Age ≥ 80 years

2.5 (1.0–6.0)

0.04

1.8 (0.5–6.1)

0.3

 ASXL1^MUT

2.5 (1.1–5.8)

0.03

1.5 (0.6–3.8)

0.3

 Complex/monosomal karyotype or chromosome 7 abnormalities

2.6 (1.4–4.8)

<0.01

2.5 (1.3–4.8)

<0.01

 PHF6^MUT variant allele fraction > 20%

2.1 (1.2–3.6)

<0.01

1.8 (1.1–3.1)

0.02

 U2AF1^MUT

1.9 (1.1–3.4)

0.02

1.9 (1.1–3.5)

0.02

 Hemoglobin < 10 g/dL

1.8 (1.1–2.9)

0.03

1.6 (0.9–2.7)

0.07

 DNMT3A^MUT

1.9 (1.0–3.6)

0.04

1.8 (0.9–3.5)

0.09

 RUNX1^MUT

1.6 (0.98–2.6)

0.056

1.5 (09–2.6)

0.1

 Complex/monosomal karyotype or chromosome 7 abnormalities

2.1 (0.9–4.6)

0.05

1.9 (0.9–4.2)

0.1

 U2AF1^MUT

2.8 (1.0–7.5)

0.04

2.4 (0.9–6.6)

0.09

 Hemoglobin < 10 g/dL

1.5 (0.7–3.2)

0.3

1.4 (0.6–3.2)

0.3

 DNMT3A^MUT

1.5 (0.7–3.3)

0.2

1.7 (0.7–3.9)

0.2

 PHF6^MUT variant allele fraction > 20%

1.9 (0.8–4.4)

0.1

1.6 (0.6–3.8)

0.3

 Complex/monosomal karyotype or chromosome 7 abnormalities

4.0 (1.0–15.5)

0.04

5.1 (1.2–20.9)

0.02

 PHF6^MUT variant allele fraction > 20%

2.6 (1.0–6.9)

0.04

3.0 (1.1–8.1)

0.02

 Hemoglobin < 10 g/dL

2.2 (0.9–5.6)

0.09

2.7 (1.0–7.2)

0.04

 DNMT3A^MUT

4.7 (1.0–21.3)

0.04

2.1 (0.2–21.9)

0.5

 U2AF1^MUT

1.9 (0.8–4.9)

0.1

1.9 (0.7–5.1)

0.1

 Hemoglobin < 10 g/dL

0.4

1.9 (0.4–10.0)

0.4

 U2AF1^MUT

1.4 (0.2–11.9)

0.8

2.3 (0.2–29.0)

0.5

 PHF6^MUT variant allele fraction > 20%

1.0 (0.2–5.1)

0.9

1.1 (0.2–6.0)

0.9

 Complex/monosomal karyotype or chromosome 7 abnormalities

1.7 (0.1–16.8)

0.6

0.9 (0.08–9.8)

0.9

 PHF6^MUT variant allele fraction > 20%

0.06

0.07

 Hemoglobin < 10 g/dL

1.2 (0.2–8.2)

0.8

1.2 (0.2–8.7)

0.8

 U2AF1^MUT

3.1 (0.3–34.8)

0.3

2.1 (0.2–23.7)

0.5

 Complex/monosomal karyotype or chromosome 7 abnormalities

<0.01

<0.01

 ASXL1^MUT

<0.01

<0.01

 Circulating blast >2%

6.0 (1.4–24.9)

0.01

5.9 (1.3–26.1)

0.01

 Abnormal karyotype except isolated loss of Y chromosome

3.3 (1.1–10.3)

0.03

2.9 (0.9–9.2)

0.07

 Female gender

2.9 (0.97–8.8)

0.05

2.3 (0.7–7.1)

0.1

 Female gender

12.9 (1.4–116.5)

0.02

26.8 (1.9–368.3)

0.01

 Abnormal karyotype except isolated loss of Y chromosome

2.6 (0.5–13.2)

0.2

7.4 (0.7–76.3)

0.09

 Female gender

0.9

0.9

 Abnormal karyotype except isolated loss of Y chromosome

4.0 (0.3–46.5)

0.2

5.1 (0.3–98.1)

0.2

 Circulating blast >2%

9.4 (0.8–108.7)

0.07

8.4 (0.7–96.7)

0.08

 Female gender

1.9 (0.2–23.6)

0.5

 Abnormal karyotype except isolated loss of Y chromosome

0.05

 Circulating blast >2%

0.9 (0.08–10.3)

0.9